14th Annual Controversies in Hematologic Malignancies Symposium
Overview
This one-day symposium will raise and address the most challenging questions in current clinical practice for hematologic malignancy. Topics will include navigating frontline therapies in Hodgkin Lymphoma, MM immunotherapies, bispecifics, renal complications of hematologic malignancies and frailty, microbiome for myeloid & transplant, and much more.
Target Audience
Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses and Allied Health Professionals
Learning Objectives
Participants who engage in this educational intervention will be able to:
- Discuss barriers to and healthcare disparities in diagnosis and treatment of multiple myeloma.
- Describe current recommendations for immunotherapy in multiple myeloma.
- Discuss relapsed/refractory indolent lymphoma therapies
- Evaluate new practice-changing data in frontline classical Hodgkin Lymphoma.
- Describe recommendations for precision medicine in myeloid malignancies as part of ongoing clinical trials
- Review the importance and benefits of interdisciplinary care for cancer patients with a focus on renal complications of hematologic malignancies and frailty
Program
7:30 - 8:25 a.m. View Exhibits/Breakfast
8:25 – 8:30 a.m. Introduction
Myeloma Block:
8:30 – 8:50 a.m. Are We Ready for Pragmatic Trials in Multiple Myeloma: Many Regimens, Trials
and Options Marcelo Pasquini, MD
8:50 – 9:30 a.m. Multiple Myeloma Immunotherapies - Targets, Timing, Sequencing, Reusing,
Alfred Garfall, MD
9:30 – 9:45 a.m. Panel Q&A with Presenters
9:45 – 10:00 a.m. Break
Lymphoma Block:
10:00 – 10:40 a.m. Treatment of Classical Hodgkin Lymphoma in the Frontline Setting,
Nilanjan Ghosh, MD, PhD
10:40 – 11:00 a.m. Relapsed/Refractory Indolent Lymphoma – Kaitlin Annunzio, MD
11:00 – 11:15 a.m. Panel Q&A with Presenters
11:15 – 11:30 a.m. Break
Breakout Sessions:
11:30 a.m. – 12:00 p.m.
BITE Therapy in the Community – Joyce Phillip, MD
Kidneys in Crisis: Navigating Renal Complications in Hematologic Malignancies – Paul Hanna, MD
Current State of Palliative Care within Hematologic Malignancies – Jordan Bauman, MD
12:00 p.m. – 12:45 p.m. Lunch
Leukemia Block:
12:45 – 1:05 p.m. Precision Medicine in Acute Myeloid Leukemia: MyeloMATCH – Laura Michaelis, MD
1:05 – 1:45 p.m. Microbiome & Nutrition in Allogeneic Hematopoietic Stem Cell Transplant – Jonathan Peled, MD
1:45 – 2:00 p.m. Panel Q&A with Presenters
2:00 p.m. Adjourn
Venue

Faculty
Name | Company | Role |
---|---|---|
Jonathan Peled, MD | Seres Therapeutics, DaVolterra, CSL Behring, Crestone, MaaT Pharma, RA Capital & Canaccord Genuity Parker Institute for Cancer Immunotherapy, Merck/Society for Immunotherapy of Cancer, Postbiotics+ Research LLC, Prodigy Biosciences | Researcher Consultant Advisory Committee Equity |
Marcelo Pasquini, MD | Bristol Myers Squibb, Kite Pharma, Novartis, Janssen Biotech | Researcher |
Nilanjan Ghosh, MD, PhD | AbbVie, AstraZeneca, Beigene, BMS, Kite pharma, Genentech/Roche, Incyte, Janssen, ADC Therapeutics, Galapagos, Ascentage Pharma Genentech/Roche, AstraZeneca, AbbVie, Pepromene, Incyte, BMS | Consultant Research |
Laura Michaelis, MD | Kuros Oncology Merck Pharmaceuticals | Review Board Presenter |
Paul Hanna, MD, MSc | Glass Health AI Amgen Pharmaceuticals | Consultant |
Sumana Devata, MD | Glaxo Smith Kline, Abbvie, Novo Nordisk, Johnson & Johnson, Eli Lilly, Merck, Pfizer, Bayer, Astra Zeneca | Stock |
Accreditation
Available Credit
- 4.25 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 4.25 Hours of ParticipationHours of Participation credit.
Register/Take course
Price
Do I already have an account?
Have you ever used ocpe.mcw.edu? For example, if you have taken an activity accredited by the Medical College of Wisconsin, then you already have an account.
If you have forgotten your username/password, you can
retrieve it now